Chapter
The Financial State of Biotech
25:43 - 30:45 (05:02)
Many public biotech stocks are now trading below their cash balance, leading to difficulty in obtaining funding for the next phase of clinical trials. The biotech industry and companies such as SYNBio now face a tense financial situation.
Clips
The CEO of a tech company discusses how they no longer focus on a blue sky case for growth, but rather prepare for the extreme bear case during uncertain times.
25:43 - 28:39 (02:55)
Business
Summary
The CEO of a tech company discusses how they no longer focus on a blue sky case for growth, but rather prepare for the extreme bear case during uncertain times.
ChapterThe Financial State of Biotech
EpisodeE80: Recession deep dive: VC psychology, macro risks, Tiger Global, predictions and more
PodcastAll-In with Chamath, Jason, Sacks & Friedberg
Roughly one third of public biotech stocks are now trading below cash, leaving them struggling to raise funds to get through the next phase of clinical trials.
28:39 - 30:45 (02:06)
Biotech Industry
Summary
Roughly one third of public biotech stocks are now trading below cash, leaving them struggling to raise funds to get through the next phase of clinical trials. While some may be rescued by pharma companies or raising more money through a secondary offering, many are no longer in a "cash game" where they can simply rebuy.